Vaccinex LONG Vacinex is a tiny company, $74 million market cap and approximately 29 million shares outstanding. They have beat street earnings expectations the past 2 quarters and they are working with Merck and the "keytruda" drug for an Alzheimer's "proof of concept" study. If the drug performs like i
−6.58USD
−19.815MUSD
275KUSD
2.042M
About Vaccinex, Inc.
Sector
Industry
CEO
Maurice Zauderer
Website
Headquarters
Rochester
Employees (FY)
43
Founded
1997
ISIN
US9186402023
Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in April 2001 and is headquartered in Rochester, NY.
VCNX Buy. $5 Exit PriceVaccinex, inc. has been in my portfolio now since March. Strong technical charting is how I came across the stock itself not fundamentals. I bought in around $1.20, but hopefully my charting shows you how low the dip is we are currently in and the obvious downwards regression channel trend. Insiders
VCNX LongHopefully you find the chart helpful in terms of Supports & Resistance etc. we refrain from adding commentary on the chart as that is reserved for our members and we are very conscious of not giving financial or trading advice. Thank you for taking time to consult our chart and we would really appre
Vaccinex Stock Analysis - VCNX Stock AnalysisTechnical Analysis,
The best option is to hold as technical analysis suggests to go short while fundamental to go long.
Fundamental Analysis
Vaccinex stock rocketed up more than 200% Friday, propelled by two collaboration deals centered on using the biotech company's antibody discovery platform
NAS
$VCNX skyrockets on Deals with Two Pharma CompaniesVaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform
Partnerships will use Vaccinex’s ActivMAb® platform for viral display of complex antigens to enable antibody discovery
www.globenewswire.com
$VCNX PT 8 and higher (@snow6)Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candi
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
